dose should be determined by the physician, according to the
requirement of the patient.
100 units/ml Junior KwikPen is suitable for patients who may benefit
from finer insulin dose adjustments.
may be given shortly before meals. When necessary Humalog can be
given soon after meals.
takes effect rapidly and has a shorter duration of activity (2 to 5
hours) given subcutaneously as compared with soluble insulin. This
rapid onset of activity allows a Humalog injection (or, in the case
of administration by continuous subcutaneous infusion, a Humalog
bolus) to be given very close to mealtime. The time course of action
of any insulin may vary considerably in different individuals or at
different times in the same individual. The faster onset of action
compared to soluble human insulin is maintained regardless of
injection site. As with all insulin preparations, the duration of
action of Humalog is dependent on dose, site of injection, blood
supply, temperature, and physical activity.
can be used in conjunction with a longer-acting insulin or oral
sulphonylurea agents, on the advice of a physician.
requirements may be reduced in the presence of renal impairment.
requirements may be reduced in patients with hepatic impairment due
to reduced capacity for gluconeogenesis and reduced insulin
breakdown; however, in patients with chronic hepatic impairment, an
increase in insulin resistance may lead to increased insulin
can be used in adolescents and children.
preparations should be given by subcutaneous injection.
KwikPen, Junior KwikPen and Tempo Pen are only suitable for
subcutaneous injections. Humalog in cartridges is only suitable for
subcutaneous injections from a Lilly reusable pen or compatible pump
systems for continuous subcutaneous insulin infusion (CSII).
administration should be in the upper arms, thighs, buttocks, or
abdomen. Use of injection sites should be rotated so that the same
site is not used more than approximately once a month in order to
reduce the risk of lipodystrophy and cutaneous amyloidosis.
administered subcutaneously care should be taken when injecting
Humalog to ensure that a blood vessel has not been entered. After
injection, the site of injection should not be massaged. Patients
must be educated to use the proper injection techniques.
KwikPen is available in two strengths. The Humalog 100 units/ml
KwikPen (and Humalog 200 units/ml KwikPen, see separate SmPC)
delivers 1 – 60 units in steps of 1 unit in a single injection.
The Humalog 100 units/ml Junior KwikPen delivers 0.5 – 30 units
in steps of 0.5 units in a single injection. The number of insulin
units is shown in the dose window of the pen regardless of strength
and no dose conversion should be done when transferring a patient to
a new strength or to a pen with a different dose step.
Humalog 100 units/ml Tempo Pen delivers 1 – 60 units in steps
of 1 unit in a single injection. The number of insulin units is shown
in the dose window of the pen regardless of strength and no dose
conversion should be done when transferring a patient to a new
strength or to a pen with a different dose step. The Tempo Pen can be
used with the optional transfer module Tempo Smart Button.
with any insulin injection, when using the Tempo Pen, Smart Button
and the mobile application, the patient should be instructed to check
their blood sugar levels when considering or making decisions about
another injection if they are unsure how much they have injected.
of Humalog in an insulin infusion pump
subcutaneous injection of Humalog using a continuous infusion pump,
you may fill the pump reservoir from a Humalog 100 units/ml vial.
Some pumps are compatible with cartridges that can be inserted intact
into the pump.
certain CE-marked insulin infusion pumps may be used to infuse
insulin lispro. Before infusing insulin lispro, the pump
manufacturer’s instructions should be studied to ascertain the
suitability for the particular pump. Use the correct reservoir and
catheter for the pump. When filling the pump reservoir avoid damaging
it by using the correct needle length on the filling system. The
infusion set (tubing and cannula) should be changed in accordance
with the instructions in the product information supplied with the
infusion set. In the event of a hypoglycaemic episode, the infusion
should be stopped until the episode is resolved. If repeated or
severe low blood glucose levels occur, consider the need to reduce or
stop an insulin infusion. A pump malfunction or obstruction of the
infusion set can result in a rapid rise in glucose levels. If an
interruption to insulin flow is suspected, follow the instructions in
the pump product literature. When used with an insulin infusion pump,
Humalog should not be mixed with any other insulin.
administration of insulin
necessary, Humalog may also be administered intravenously, for
example: for the control of blood glucose levels during ketoacidosis,
acute illnesses or during intra and post operative periods.
100 units /ml is available in vials if administration of intravenous
injection is necessary.
injection of insulin lispro should be carried out following normal
clinical practise for intravenous injections, for example by an
intravenous bolus or by an infusion system. Frequent monitoring of
the blood glucose levels is required.
systems at concentrations from 0.1 units/ml to 1.0 units/ml insulin
lispro in 0.9 % sodium chloride or 5 % dextrose are stable at room
temperature for 48 hours. It is recommended that the system is primed
before starting the infusion to the patient.
100 Units/ml [Summary of Product Characteristics]. Utrecht, The
Netherlands: Eli Lilly Nederland B.V.